- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04203862
A Study of NPC-22 in Healthy Adult Males
August 5, 2020 updated by: Nobelpharma
A Phase 1 Single Ascending Dose Study of NPC-22 in Healthy Adult Males
The purpose of this trial is to examine the safety and pharmacokinetics of NPC-22 administered in a single ascending dose in healthy adult males.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The healthy adult males will be randomized into six arms, and will receive single dose of NPC-22 (five doses, placebo)
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tokyo
-
Shinjuku, Tokyo, Japan, 160-0017
- Medical Corporation Shinanokai Shinanozaka Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Subjects who have provided their own written informed consent
- Subjects aged ≥20 and <40 years at the time of informed consent
- Subjects with body weight of ≥50 kg and body mass index (BMI) (kg/m2) of ≥18.5 and <25.0
- Subjects who were identified to have no health problem on physical examination, physical assessment, laboratory tests, or other examinations at screening by the principal investigator or a sub-investigator
Exclusion Criteria:
- Subjects with a complication or a history of drug abuse (use of an illicit drug) or alcohol dependence
- Subjects with a history of severe disease that may recur during the study period
- Subjects with any concurrent illnesses
- Subjects who received another study drug within 180 days prior to the start of study drug administration
- Subjects who donated blood of ≥400 mL within 12 weeks, blood of ≥200 mL within 4 weeks, or blood components within 2 weeks prior to the start of the study
- Subjects who used any medicinal product (including over the counter drugs except for topical products) or similar product like a dietary supplement (including health food) within 7 days prior to the start of study drug administration
- Subjects who took any food or beverage containing grapefruit or St. John's wort within 7 days prior to the start of study drug administration
- Subjects who took any alcohol or caffeine-containing beverage within 3 days prior to the start of study drug administration
- Subjects who smoked within 90 days prior to the start of study drug administration, or do not agree to stop smoking during the study period
- Subjects who had a positive result for HBs antigen, HCV antibody, or HIV antigen/antibody, or a positive reaction to syphilis serology or urine drug test at screening
- Subjects who are unsuitable as a subject in this study in the judgement of the principal investigator or a sub-investigator based on the 12-lead electrocardiogram at screening [e.g., Fridericia's corrected QT (QTcF) interval of ≥450 ms]
- Subjects who have a familial history of torsades de pointes or long QT syndrome
- Subjects who are unsuitable as a subject in this study in the judgement of the principal investigator or a sub-investigator by having a deviation from the institutional reference values
- Subjects who are unsuitable as a subject in this study in the judgement of the principal investigator or a sub-investigator due to other reasons
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Single administration of low dose NPC-22
|
Single administration of middle dose NPC-22
Single administration of high dose NPC-22
Single administration of low dose NPC-22
Single administration of low/middle dose NPC-22
Single administration of middle/high dose NPC-22
|
Experimental: 2
Single administration of low/middle dose NPC-22
|
Single administration of middle dose NPC-22
Single administration of high dose NPC-22
Single administration of low dose NPC-22
Single administration of low/middle dose NPC-22
Single administration of middle/high dose NPC-22
|
Experimental: 3
Single administration of middle dose NPC-22
|
Single administration of middle dose NPC-22
Single administration of high dose NPC-22
Single administration of low dose NPC-22
Single administration of low/middle dose NPC-22
Single administration of middle/high dose NPC-22
|
Experimental: 4
Single administration of middle/high dose NPC-22
|
Single administration of middle dose NPC-22
Single administration of high dose NPC-22
Single administration of low dose NPC-22
Single administration of low/middle dose NPC-22
Single administration of middle/high dose NPC-22
|
Experimental: 5
Single administration of high dose NPC-22
|
Single administration of middle dose NPC-22
Single administration of high dose NPC-22
Single administration of low dose NPC-22
Single administration of low/middle dose NPC-22
Single administration of middle/high dose NPC-22
|
Experimental: 6
Single administration of placebo dose NPC-22
|
Single administration of NPC-22 Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: 0-7 days post dose
|
An adverse event will refer to any unfavorable or unintended sign (including an abnormal laboratory finding and abnormality on the 12-lead ECG or in vital signs) and symptom
|
0-7 days post dose
|
Body temperature
Time Frame: 0-7 days post dose
|
Body temperature will be measured for assess the safety of single ascending dose of NPC-22
|
0-7 days post dose
|
Blood pressure
Time Frame: 0-7 days post dose
|
Blood pressure will be measured for assess the safety of single ascending dose of NPC-22
|
0-7 days post dose
|
Pulse rate
Time Frame: 0-7 days post dose
|
Pulse rate will be measured for assess the safety of single ascending dose of NPC-22
|
0-7 days post dose
|
ECG
Time Frame: 0-7 days post dose
|
RR, PR, QRS, QT and QTcF interval and heart rate will be measured for assess the safety of single ascending dose of NPC-22
|
0-7 days post dose
|
Number and/or rates of subjects with treatment-related adverse events as assessed by hematology tests
Time Frame: 0-7 days post dose
|
Hematology tests will be performed for assessment the safety of single ascending dose of NPC-22
|
0-7 days post dose
|
Number and/or rates of subjects with treatment-related adverse events as assessed by blood chemistry tests
Time Frame: 0-7 days post dose
|
Blood chemistry tests will be performed for assessment the safety of single ascending dose of NPC-22
|
0-7 days post dose
|
Number and/or rates of subjects with treatment-related adverse events as assessed by urinalysis
Time Frame: 0-7 days post dose
|
Urinalysis will be performed for assessment the safety of single ascending dose of NPC-22
|
0-7 days post dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Observed plasma concentration
Time Frame: 0-7 days post dose
|
0-7 days post dose
|
Observed urine concentration
Time Frame: 0-4 days post dose
|
0-4 days post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 19, 2019
Primary Completion (Actual)
February 4, 2020
Study Completion (Actual)
February 4, 2020
Study Registration Dates
First Submitted
November 17, 2019
First Submitted That Met QC Criteria
December 16, 2019
First Posted (Actual)
December 18, 2019
Study Record Updates
Last Update Posted (Actual)
August 6, 2020
Last Update Submitted That Met QC Criteria
August 5, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- NPC-22
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Adult Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
China Resources Biopharmaceutical Co., LtdPeking University Third HospitalRecruiting
-
Auzone Biological Technology Pty LtdCompleted
-
Mitsubishi Tanabe Pharma CorporationCompletedHealthy Adult SubjectsJapan
-
Alvotech Swiss AGIqvia Pty LtdCompletedHealthy Adult SubjectsNew Zealand, United Kingdom
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Connect Biopharma Australia Pty LtdCompletedHealthy Adult SubjectsAustralia
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHealthy Adult SubjectsChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
Clinical Trials on NPC-22
-
NobelpharmaCompleted
-
NobelpharmaCompletedCytomegalovirus DiseaseUnited States, Japan
-
NobelpharmaTerminatedNeuropathic Pain in CancerJapan
-
Cedars-Sinai Medical CenterCalifornia Institute for Regenerative Medicine (CIRM)Recruiting
-
Tohoku UniversityCompletedHereditary Inclusion Body Myopathy | Nonaka MyopathyJapan
-
NobelpharmaCompletedGNE Myopathy | Nonaka Disease | Distal Myopathy With Rimmed Vacuoles (DMRV) | Hereditary Inclusion Body Myopathy (hIBM)Japan
-
Medical University of South CarolinaJohns Hopkins University; University of North Carolina; Cook Endoscopy; Thoraxklinik-Heidelberg...CompletedQuantity of Tissue Obtained | Quality of Tissue Obtained | Ease of Use of 22-gauge ProCore EBUS Needles and the Standard 22-gauge NeedlesUnited States
-
Unilever R&DLeiden University Medical CenterCompleted
-
Aalborg UniversityUnknown
-
NobelpharmaCompleted